Osteoporosis: a clinical and pharmacological update

Clin Rheumatol. 2019 Feb;38(2):385-395. doi: 10.1007/s10067-018-4370-1. Epub 2018 Dec 12.

Abstract

Osteoporosis is characterized by the loss of bone mass, deterioration of the bone microarchitecture, and an increased risk of fractures; these later complications are associated with significant morbidity and mortality. The asymptomatic and progressive nature of osteoporosis underscores the importance of identifying this entity in early stages. Despite the various treatments available, the prevention of the disease represents the most important aspect of management. An adequate intake of calcium and vitamin D as well as a healthy lifestyle is the basis for maintaining bone health. When osteoporosis is diagnosed, the choice of medications must be individualized considering characteristics of the patient and the risk of fractures. In this article, we review the main causes of osteoporosis, when and how to start treatment, and appropriate therapy and monitoring.

Keywords: Bone mineral density; Fractures; Osteoporosis; Osteoporosis treatment.

Publication types

  • Review

MeSH terms

  • Anabolic Agents / therapeutic use
  • Bone Density
  • Bone Density Conservation Agents / therapeutic use
  • Calcium, Dietary / therapeutic use
  • Female
  • Fractures, Bone / epidemiology*
  • Fractures, Bone / etiology
  • Glucocorticoids / adverse effects
  • Healthy Lifestyle
  • Humans
  • Male
  • Osteoporosis / chemically induced
  • Osteoporosis / diagnosis*
  • Osteoporosis / drug therapy*
  • Sex Factors
  • Vitamin D / therapeutic use
  • Vitamin D Deficiency / complications
  • Vitamin D Deficiency / drug therapy*

Substances

  • Anabolic Agents
  • Bone Density Conservation Agents
  • Calcium, Dietary
  • Glucocorticoids
  • Vitamin D